← Patent-cliff monitor small molecule RHAPSIDO REMIBRUTINIB
Loss of exclusivity January 2043 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name RHAPSIDO Active ingredient REMIBRUTINIB Strength 25MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval September 2025 Marketing status RX
Listed patents Patent Expires Type 12419889 January 2043 use U-4281 10457647 November 2034 use U-4280 9512084 November 2034 substance, product
Regulatory exclusivity Code Expires NCE September 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.